Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301EXT is an
open-label, nonrandomized, phase 1 extension study of PSMA ADC administered IV in subjects
with progressive CMPC that has progressed after prior taxane therapy. Subjects who have
participated in PSMA ADC 1301 and who, in the opinion of the PI, are likely to benefit from
continued treatment with PSMA ADC will be enrolled in PSMA ADC 1301EXT.